Patents by Inventor Laust Bruun Johnsen

Laust Bruun Johnsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Procoagulant Antibodies
    Publication number: 20230058721
    Abstract: The present invention relates to multispecific procoagulant antibodies capable of binding to coagulation Factor IX (FIX) and/or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and/or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes or parts thereof and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A as well as kits, methods of manufacture and methods of use.
    Type: Application
    Filed: November 10, 2021
    Publication date: February 23, 2023
    Inventors: Karina Thorn, Bjarne Gram Hansen, Laust Bruun Johnsen, Mikkel Nors Harndahl, Zhiru Yang, Henrik Oestergaard, Per J. Greisen, Eva Johansson, Morten Groenbech Rasch, Jianhe Chen, Anders Svensson, Haisun Zhu, Rong Zhou, Prafull S. Gandhi
  • Procoagulant antibodies
    Patent number: 11220554
    Abstract: The present invention relates to multispecific procoagulant antibodies capable of binding to coagulation Factor IX (FIX) and/or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and/or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes or parts thereof and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A as well as kits, methods of manufacture and methods of use.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: January 11, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Karina Thorn, Bjarne Gram Hansen, Laust Bruun Johnsen, Mikkel Nors Harndahl, Zhiru Yang, Henrik Oestergaard, Per J. Greisen, Eva Johansson, Morten Groenbech Rasch, Jianhe Chen, Anders Svensson, Haisun Zhu, Rong Zhou, Prafull S. Gandhi
  • Procoagulant Antibodies
    Publication number: 20210388114
    Abstract: The present invention relates to improved procoagulant antibodies including bispecific antibodies capable of binding to coagulation Factor IX (FIX) or the activated form thereof Factor IXa (FIXa) and optionally Factor X (FX) and the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A.
    Type: Application
    Filed: February 1, 2018
    Publication date: December 16, 2021
    Inventors: Karina Thorn, Bjarne Gram Hansen, Laust Bruun Johnsen, Mikkel Nors Harndahl, Zhiru Yang, Henrik Oestergaard, Per J. Greisen, Eva Johansson, Morten Groenbech Rasch, Jianhe Chen, Anders Svensson, Haisun Zhu, Rong Zhou, Prafull S. Gandhi
  • PROCOAGULANT ANTIBODIES
    Publication number: 20210238306
    Abstract: The present invention relates to multispecific procoagulant antibodies capable of binding to coagulation Factor IX (FIX) and/or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and/or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes or parts thereof and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A as well as kits, methods of manufacture and methods of use.
    Type: Application
    Filed: January 29, 2021
    Publication date: August 5, 2021
    Inventors: Karina Thorn, Bjarne Gram Hansen, Laust Bruun Johnsen, Mikkel Nors Harndahl, Zhiru Yang, Henrik Oestergaard, Per J. Greisen, Eva Johansson, Morten Groenbech Rasch, Jianhe Chen, Anders Svensson, Haisun Zhu, Rong Zhou
  • Factor VIII variants having a decreased cellular uptake
    Patent number: 10906960
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: February 2, 2021
    Assignee: SANQUIN BLOOD SUPPLY FOUNDATION
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnes Kjalke, Henning Ralf Stennicke, Johannes Jacobus Voorberg, Maartje Van Den Biggelaar
  • Factor VIII Variants Having A Decreased Cellular Uptake
    Publication number: 20180327479
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Application
    Filed: July 6, 2018
    Publication date: November 15, 2018
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnes Kjalke, Henning Ralf Stennicke, Johannes Jacobus Voorberg, Maartje Van Den Biggelaar
  • Factor VIII variants having a decreased cellular uptake
    Patent number: 10047142
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: August 14, 2018
    Assignees: Novo Nordisk A/S, Sanquin Blood Supply Foundation
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnes Kjalke, Henning Ralf Stennicke, Johannes Jacobus Voorberg, Maartje Van Den Biggelaar
  • Factor VIII polypeptide titers in cell cultures
    Patent number: 9982033
    Abstract: The invention relates to a method for the production of a Factor VIII polypeptide, the method comprising the steps of a) culturing a mammalian cell expressing a Factor VIII polypeptide under conditions for expression of said Factor VIII polypeptide, said culturing conditions involving a cell culture medium comprising a C2-domain ligand, and b) isolating the expressed Factor VIII polypeptide from the mammalian cell by suitable means.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: May 29, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Laust Bruun Johnsen, Ida Hilden, Gert Bolt, Thomas Dock Steenstrup
  • FACTOR VIII VARIANTS HAVING A DECREASED CELLULAR UPTAKE
    Publication number: 20170066813
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Application
    Filed: November 18, 2016
    Publication date: March 9, 2017
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnes Kjalke, Henning Ralf Stennicke, Johannes Jacobus Voorberg, Maartje Van Den Biggelaar
  • Factor VIII variants having a decreased cellular uptake
    Patent number: 9321827
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: April 26, 2016
    Assignees: Novo Nordisk A/S, Sanquin Blood Supply Foundation
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnæs Kjalke, Henning Ralf Stennicke, Johannes Voorberg, Maartje Van Den Biggelaar
  • FACTOR VIII VARIANTS HAVING A DECREASED CELLULAR UPTAKE
    Publication number: 20160002314
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Application
    Filed: September 23, 2015
    Publication date: January 7, 2016
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Kjalke, Henning Ralf Stennicke, Johannes Jacobus Voorberg, Maartje Van Den Biggelaar
  • METHOD FOR PRODUCTION OF FACTOR VIII
    Publication number: 20140308707
    Abstract: The present invention relates to methods of producing a Factor VIII polypeptide in mammalian cell cultures.
    Type: Application
    Filed: November 2, 2012
    Publication date: October 16, 2014
    Inventors: Laust Bruun Johnsen, Mille Petersen Kolind, Peder Lisby Noerby
  • FACTOR VIII VARIANTS HAVING A DECREASED CELLULAR UPTAKE
    Publication number: 20140057848
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modified Factor VIII molecules having decreased cellular uptake.
    Type: Application
    Filed: September 14, 2011
    Publication date: February 27, 2014
    Applicant: NOVO NORDISK A/S
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnæs Kjalke, Henning Ralf Stennicke, Johannes Voorberg, Maartje Van Den Biggelaar
  • FACTOR VIII POLYPEPTIDE TITERS IN CELL CULTURES
    Publication number: 20100120094
    Abstract: The invention relates to a method for the production of a Factor VIII polypeptide, the method comprising the steps of a) culturing a mammalian cell expressing a Factor VIII polypeptide under conditions for expression of said Factor VIII polypeptide, said culturing conditions involving a cell culture medium comprising a C2-domain ligand, and b) isolating the expressed Factor VIII polypeptide from the mammalian cell by suitable means.
    Type: Application
    Filed: April 30, 2008
    Publication date: May 13, 2010
    Applicant: NOVO NORDISK A/S
    Inventors: Laust Bruun Johnsen, Ida Hilden, Gert Bolt, Thomas Dock Steenstrup